Tamara García-Salum

Tamara García-Salum

Auto-generated profile, based on publicly available information

Tamara García-Salum

Emory Vaccine Center, Emory University School of Medicine, Atlanta, GA 30317, USA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 September 2022 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
QZQian Zhang
Qian Zhang
MPMario Andrés Pizzorno
Mario Andrés Pizzorno
LMLisa Miorin
Lisa Miorin
PBPaul Bastard
Paul Bastard
AGAdrian Gervais
Adrian Gervais
JCJean-Laurent Casanova
Jean-Laurent Casanova
Autoantibodies neutralizing type I interferons (IFNs) can underlie critical COVID-19 pneumonia and yellow fever vaccine disease. We report here on 13 patients harboring autoantibodies neutralizing IFN-α2 alone (five patients) or with IFN-ω (eight patients) from a cohort of 279 patients (4.7%) aged 6–73 yr with critical influenza pneumonia. Nine and four patients had antibodies neutralizing high and low concentrations, respectively, of IFN-α2, and six and two patients had antibodies neutralizing high and low concentrations, respectively, of IFN-ω. The patients’ autoantibodies increased influenza A virus replication in both A549 cells and reconstituted human airway epithelia. The prevalence of these antibodies was significantly higher than that in the general population for patients 70 yr of age (3.1 vs. 4.4%, P = 0.68). The risk of critical influenza was highest in patients with antibodies neutralizing high concentrations of both IFN-α2 and IFN-ω (OR = 11.7, P = 1.3 × 10−5), especially those <70 yr old (OR = 139.9, P = 3.1 × 10−10). We also identified 10 patients in additional influenza patient cohorts. Autoantibodies neutralizing type I IFNs account for ∼5% of cases of life-threatening influenza pneumonia in patients <70 yr old.

27 April 2022 in Science Translational Medicine
Verified
Journal Article
Open access
YBYannic C. Bartsch
Yannic C. Bartsch
XTXin Tong
Xin Tong
JKJaewon Kang
Jaewon Kang
MAMaría José Avendaño
María José Avendaño
ESEileen F. Serrano
Eileen F. Serrano
GAGalit Alter
Galit Alter
The Omicron variant of SARS-CoV-2 has been shown to evade neutralizing antibodies elicited by vaccination or infection. Despite the global spread of the Omicron variant, even among highly vaccinated populations, death rates have not increased concomitantly. These data suggest that immune mechanisms beyond antibody-mediated virus neutralization may protect against severe disease. In addition to neutralizing pathogens, antibodies contribute to control and clearance of infections through Fc effector mechanisms. Here, we probed the ability of vaccine-induced antibodies to drive Fc effector activity against the Omicron variant using samples from individuals receiving one of three SARS-CoV-2 vaccines. Despite a substantial loss of IgM, IgA, and IgG binding to the Omicron variant receptor binding domain (RBD) in samples from individuals receiving BNT162b2, mRNA-1273, and CoronaVac vaccines, stable binding was maintained against the full-length Omicron Spike protein. Compromised RBD binding IgG was accompanied by a loss of RBD-specific antibody Fcγ receptor (FcγR) binding in samples from individuals who received the CoronaVac vaccine, but RBD-specific FcγR2a and FcγR3a binding was preserved in recipients of mRNA vaccines. Conversely, Spike protein–specific antibodies exhibited persistent but reduced binding to FcγRs across all three vaccines, although higher binding was observed in samples from recipients of mRNA vaccines. This was associated with preservation of FcγR2a and FcγR3a binding antibodies and maintenance of Spike protein–specific antibody-dependent natural killer cell activation. Thus, despite the loss of Omicron neutralization, vaccine-induced Spike protein–specific antibodies continue to drive Fc effector functions, suggesting a capacity for extraneutralizing antibodies to contribute to disease control.

21 August 2024 in Science Translational Medicine
Verified
Journal Article
Closed access
PDPritesh Desai
Pritesh Desai
CKCourtney E. Karl
Courtney E. Karl
BYBaoling Ying
Baoling Ying
CLChieh-Yu Liang
Chieh-Yu Liang
TGTamara Garcia-Salum
Tamara Garcia-Salum
MDMichael Diamond
Michael Diamond
Although vaccines have reduced the burden of COVID-19, their efficacy in helminth infection–endemic areas is not well characterized. We evaluated the impact of infection by Heligmosomoides polygyrus bakeri (Hpb), a murine intestinal roundworm, on the efficacy of an mRNA vaccine targeting the Wuhan-1 spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in mice. Although immunization generated similar B cell responses in Hpb-infected and uninfected mice, polyfunctional CD4 + and CD8 + T cell responses were markedly reduced in Hpb-infected mice. Hpb-infected and mRNA-vaccinated mice were protected against the ancestral SARS-CoV-2 strain WA1/2020, but control of lung infection was diminished against an Omicron variant compared with animals immunized without Hpb infection. Helminth-mediated suppression of spike protein–specific CD8 + T cell responses occurred independently of signal transducer and activator of transcription 6 (STAT6) signaling, whereas blockade of interleukin-10 (IL-10) rescued vaccine-induced CD8 + T cell responses. Together, these data show that, in mice, intestinal helminth infection impaired vaccine-induced T cell responses through an IL-10 pathway, which compromised protection against antigenically drifted SARS-CoV-2 variants.

18 May 2021 in medRxiv
Verified
Preprint
Open access
PDF file
NMNicolas Alvaro Muena
Nicolas Alvaro Muena
TGTamara García-Salum
Tamara García-Salum
CPCatalina Pardo-Roa
Catalina Pardo-Roa
ESEileen F. Serrano
Eileen F. Serrano
JLJorge Levican
Jorge Levican
RMRafael A. Medina
Rafael A. Medina
The durability of circulating neutralizing antibody (nAb) responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and their boosting by vaccination remains to be defined. We show that outpatient and hospitalized SARS-CoV-2 seropositive individuals mount a robust neutralizing antibody (nAb) response that peaks at days 23 and 27 post-symptom onset, respectively. Although nAb titers remained higher in hospitalized patients, both study groups showed long-lasting nAb responses that can persist for up to 12 months after natural infection. These nAb responses in previously seropositive individuals can be significantly boosted through immunization with two doses of the CoronaVac (Sinovac) or one dose of the BNT162b2 (BioNTech/Pfizer) vaccines, suggesting a substantial induction of B cell memory responses. Noteworthy, three obese previously seropositive individuals failed to mount a booster response upon vaccination, warranting further studies in this population. Immunization of naïve individuals with two doses of the CoronaVac vaccine or one dose of the BNT162b2 vaccine elicited similar levels of nAbs compared to seropositive individuals 4.2 to 13.3 months post-infection with SARS-CoV-2. Thus, this preliminary evidence suggests that both, seropositive and naïve individuals, require two doses of CoronaVac to ensure the induction of robust nAb titers.

12 October 2022 in Pediatric Obesity
Verified
Journal Article
Closed access
GGGonzalo Hernan Valenzuela Galaz
Gonzalo Hernan Valenzuela Galaz
GAGonzalo Alarcón‐Andrade
Gonzalo Alarcón‐Andrade
CSClara Schulze‐Schiapacasse
Clara Schulze‐Schiapacasse
RRRocío Rodríguez
Rocío Rodríguez
TGTamara García‐Salum
Tamara García‐Salum
RMRafael A. Medina
Rafael A. Medina